The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for September 2018 (PDF).
This issue advises that valproate medicines must not be used in women of childbearing potential unless the Pregnancy Prevention Programme is in place. The reminder contains links resources and previous drug safety articles.
Also this month, the summary of letters to healthcare professionals includes a copy of information sent regarding the new contraindications and liver monitoring requirements for ulipristal acetate (Esmya®).
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.